TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04907110

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen
Description: Participants in the NR supplementation + exercise group will undergo oral NR supplementation for 40 days. NiagenTM is the name for the dietary supplement containing NR (ChromaDex, Inc. Irvine, USA). The total dosage of NR per day will be 1000mg. This supplementation time of 40 days 1000mg/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: During days 17-38 of the NR/placebo intake, participants will perform a 3-weeks supervised exercise training program with four \~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: During days 17-38 of the NR/placebo intake, participants will perform a 3-weeks supervised exercise training program with four \~30 min exercise sessions per week (two endurance session on a bike at 70%Wmax and two high intensity interval (HIIT) sessions.
Study: NCT04973878

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EGD first
Description: In this group, patients receiving an EGD followed by a colonoscopy during a same-day bidirectional endoscopy. Patients receive deep sedation with propofol and fentanyl.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy first
Description: In this group, patients receiving a colonoscopy followed by EGD during a same-day bidirectional endoscopy. Patients receive deep sedation with propofol and fentanyl.
Study: NCT05839756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: 2 ml nebulized budesonide (containing 1 mg) diluted in 3 ml of normal saline will be nebulized preoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 5 ml normal saline will be nebulized preoperatively
Study: NCT05185986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Pilates exercise
Description: The Home-based Pilates is the two Pilates classes at home, twice weekly, for a period of eight weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Pilates exercise
Description: The Home-based Pilates is the two Pilates classes at home, twice weekly, for a period of eight weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Cognitive Rehabilitation
Description: Home-based Cognitive Rehabilitation is the 3 sessions per week and 8 weeks of cognitive rehabilitation exercises at home. Each session consists of two Pen and paper exercises. Exercises are active in the areas of planning, cognitive organization, cognitive flexibility and working memory. Each session will take 30 to 45 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: waiting list group
Description: This group act as the control group and will maintain their physical and cognitive activities as the preintervention. Following the 8 weeks of intervention the home-based pilates and cognitive rehabilitation exercises will be provided to them for their own use.
Study: NCT06319690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lion's Breath Technique
Description: Patients receive training in Lion's Breath Technique, emphasizing deep diaphragmatic breathing and controlled exhalation.~Daily supervised Lion's Breath Technique sessions for 20 minutes for 1 week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest Percussion Therapy
Description: Trained physiotherapists administer chest percussion therapy to mobilize secretions and improve lung function.~Daily session for 30 minutes for 1 week.
Study: NCT06452004

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Validation of AI-DSS in Bangladesh
Description: VIA procedure, taking pre-colouring and post-colouring pictures. First VIA assessment by health worker, followed by AI-DSS assessment. Independent panel of gynaecologists also assessed pictures. The panel assessment serves as reference value to calculate accuracy, sensitivity and specificity of health worker and AI-DSS.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Validation of AI-DSS in Uganda
Description: VIA procedure, taking pre-colouring and post-colouring pictures. First VIA assessment by health worker, followed by AI-DSS assessment. Independent panel of gynaecologists also assessed pictures. The panel assessment serves as reference value to calculate accuracy, sensitivity and specificity of health worker and AI-DSS.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Validation of AI-DSS in India
Description: VIA procedure, taking pre-colouring and post-colouring pictures. First VIA assessment by health worker, followed by AI-DSS assessment. Independent panel of gynaecologists also assessed pictures. The panel assessment serves as reference value to calculate accuracy, sensitivity and specificity of health worker and AI-DSS.
Study: NCT04916041

Intervention type: DEVICE
Intervention: Cataract surgery with bilateral implantation of the same type of intraocular lens
Description: Cataract surgery with bilateral implantation of the same type of intraocular lens

Intervention type: DEVICE
Intervention: Cataract surgery with bilateral implantation of the same type of intraocular lens
Description: Cataract surgery with bilateral implantation of the same type of intraocular lens

Intervention type: DEVICE
Intervention: Cataract surgery with bilateral implantation of the same type of intraocular lens
Description: Cataract surgery with bilateral implantation of the same type of intraocular lens

Intervention type: DEVICE
Intervention: Cataract surgery with bilateral implantation of the same type of intraocular lens
Description: Cataract surgery with bilateral implantation of the same type of intraocular lens

Intervention type: DEVICE
Intervention: Cataract surgery with bilateral implantation of the same type of intraocular lens
Description: Cataract surgery with bilateral implantation of the same type of intraocular lens
Study: NCT04635683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Given PO
Study: NCT06319690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest Percussion Therapy
Description: Trained physiotherapists administer chest percussion therapy to mobilize secretions and improve lung function.~Daily session for 30 minutes for 1 week.
Study: NCT05864859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation
Description: In the simulation session, while 2 participants (1 midwife, 1 pregnant) performed the roles in accordance with the clinical scenario, the performance was recorded in the control room. A Wearable Pregnancy Simulator was worn by the student performing the pregnant role. During the simulation, the participants were able to interact with the facilitators when they had questions. The application time did not exceed 10 minutes.
Study: NCT05535634

Intervention type: DIAGNOSTIC_TEST
Intervention: Sound Ear Check
Description: Hearing test, measurement of the input impedance of the middle-ear transmission system
Study: NCT05267613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium 20mg
Description: Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
Study: NCT06153771

Intervention type: OTHER
Intervention: Collection of brain and kidney NIRS measurements
Description: (recorded continuously) by a person not involved in the study 30 minutes before echocardiography was performed

Intervention type: OTHER
Intervention: echocardiography
Description: on day 2, day 4 and day 7 of life
Study: NCT05097716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 200 mg provided as four 50 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: Tolbutamide 500 mg provided as one 500 mg oral tablet
Study: NCT05410353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Intervention Group
Description: The 3 major intervention components are diet, physical activity, and the behavioral modification curriculum. Scheduled interactions are educational podcasts (a series of audiovisual, digital media files) paired with a follow-up phone counseling session with a trained behavioral interventionist. A patient portal message will be sent to participants when a new podcast is posted. Interactive sessions will be weekly (weeks 1-16), biweekly (weeks 17-24), and monthly (weeks 25-52). The goal for weight loss is ≥ 7% of initial weight over the course of 12 months. Participants will restrict caloric intake with the goal of 1,200-1,500 kcal/day for those weighing \< 114 kg and 1,500-1,800 kcal/day for those weighing ≥ 114 kg. The physical activity goal will be for participants to gradually increase to 175-200 minutes of moderate-intensity activity per week by the 24th week. Participants will also be asked to self-monitor their dietary intake and physical activity using the Lose It! app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison Group
Description: All participants in the Comparison Group will receive a mandatory 13 contacts per year including 3 informational sessions on nutrition, physical activity and social support and 10 contacts via patient portal or email regarding intervention topics. The Look AHEAD Comparison Group was designed to be realistic, achievable, and an acceptable intervention that encouraged optimal study retention.
Study: NCT06333288

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PST-APPLE Watch group
Description: PST combined APPLE Watch is a tailored behavioral intervention that enables college students with AUD to successfully manage and overcome everyday life challenges influencing their alcohol intake and teach problem-solving skills.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education-only control group
Description: Education-only control group receives Quit Drinking Motivation 20-min video created by the MotivationHub, followed by a 30-minute group discussion.
Study: NCT05621616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: Participants will receive mirabegron prolonged-release microgranula-based oral suspension once daily. The initial dose of mirabegron will be based on the participant's weight.~The initial low dose will be up-titrated to a higher dose at weeks 2, 4 or 8 unless the participant is determined to be effectively treated with the low dose, based on urodynamics and the participants'e-diary.
Study: NCT06292650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-02-L
Description: rAAV-PsCatCh2.0 intravitreal injection of low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZM-02-H
Description: rAAV-PsCatCh2.0 intravitreal injection of high dose

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ZM-02-S
Description: sham intravitreal injection of ZM-02 (not actual injection)
Study: NCT06564844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: Datopotamab Deruxtecan IV (intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Rilvegostomig IV (intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Rilvegostomig IV (intravenous)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV (intravenous), Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin IV (intravenous), Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide IV (intravenous), Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed IV (intravenous), Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine IV (intravenous), Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UFT
Description: UFT Oral route of administration, Active Comparator
Study: NCT04903106

Intervention type: DEVICE
Intervention: FAST-FIX FLEX Meniscal Repair System
Description: Standard of care surgery in which the meniscus is repaired using FAST-FIX FLEX device.

Intervention type: DEVICE
Intervention: FAST-FIX FLEX Meniscal Repair System
Description: Standard of care surgery in which the FASTFIX FLEX device is used during the meniscal allograft transplantation procedure.
Study: NCT04662151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT-100
Description: reconstituted AT-100 for intratracheal administration

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Air-sham
Description: room air for intratracheal administration
Study: NCT05091723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nezulcitinib (TD-0903) Dose A
Description: TD-0903 Dose A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nezulcitinib (TD-0903) Dose A
Description: TD-0903 Dose A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nezulcitinib (TD-0903) Dose A
Description: TD-0903 Dose A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nezulcitinib (TD-0903) Dose B
Description: TD-0903 Dose B
Study: NCT06295835

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fingerstick blood draw
Description: Capillary blood specimen collected from two separate fingersticks.
Study: NCT04908605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Every patient will be given mirtazapine 30 mg tablet
Study: NCT05267613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium 10mg
Description: Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
Study: NCT04908605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Every patient will be given melatonin 5 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Every patient will be given a matching placebo tablet
Study: NCT05867953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging
Description: Biopsy with the Robotic- Navigational Bronchoscopy System with Adjunct Real-time Imaging
Study: NCT05400642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: Apneic ventilation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation
Description: mechanical ventilation in Positive Pressure
Study: NCT04630756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4573
Description: AZD4573 will be administered as an absolute (flat) dose, 2-hour (± 15 minutes) IV infusion once weekly (as monotherapy for Module 2 only) and in combination with orally administered acalabrutinib twice daily continuously. For both Part A and Part B of this study, Cycle 1 consists of 5 weeks, with a dose ramp-up. Subsequent cycles are 21 days (3 weeks) with once weekly dosing of AZD4573 in combination with acalabrutinib twice daily continuously (in Module 1 and Module 2, period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4573
Description: AZD4573 will be administered as an absolute (flat) dose, 2-hour (± 15 minutes) IV infusion once weekly (as monotherapy for Module 2 only) and in combination with orally administered acalabrutinib twice daily continuously. For both Part A and Part B of this study, Cycle 1 consists of 5 weeks, with a dose ramp-up. Subsequent cycles are 21 days (3 weeks) with once weekly dosing of AZD4573 in combination with acalabrutinib twice daily continuously (in Module 1 and Module 2, period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Oral Acalabrutinib capsule will be administered twice daily continuously from Day 1 of Cycle 1 Week 1 in combination with AZD4573.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Oral Acalabrutinib capsule will be administered twice daily continuously from Day 1 of Cycle 1 Week 1 in combination with AZD4573.
Study: NCT06054412

Intervention type: DEVICE
Group type: OTHER
Intervention: Neuroptimal (Zengar, Inc.) Neurofeedback
Description: Mothers in the Neurofeedback Training group will complete one training session (lasting approximately 33 minutes) a week for a total of 12 weeks, using the Neuroptimal (Zengar, Inc.) neurofeedback device.
Study: NCT04866368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The ultrasound-guided Sacral Erector spinae plane block
Description: postoperative pain procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The dorsal penile block
Description: postoperative pain procedure
Study: NCT06007742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: parent-administered pediatric tuina
Description: Parents in intervention group will participate in a pediatric tuina course to improve eating and sleep symptoms of ADHD, followed by an 8-week treatment period for the children. The course will take place at the Hong Kong Polytechnic University campus and will consist of 2 sessions of approximately 2 hours each. The course content will be taught by a registered TCM practitioner.~. Parents assigned to this group will participate in a Parent-Child Exercise for ADHD program, which will complete with their children in the next 8 weeks. The program will take place at the Hong Kong Polytechnic University campus and will consist of 2 sessions of approximately 2 hours each. The content will be taught by a registered physiotherapist.~The two intervention groups are manipulated every other day for 25-30 minutes each. A total number of interventions equal to or greater than 24 is considered a completed intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: parent-administered pediatric tuina
Description: Parents in intervention group will participate in a pediatric tuina course to improve eating and sleep symptoms of ADHD, followed by an 8-week treatment period for the children. The course will take place at the Hong Kong Polytechnic University campus and will consist of 2 sessions of approximately 2 hours each. The course content will be taught by a registered TCM practitioner.~. Parents assigned to this group will participate in a Parent-Child Exercise for ADHD program, which will complete with their children in the next 8 weeks. The program will take place at the Hong Kong Polytechnic University campus and will consist of 2 sessions of approximately 2 hours each. The content will be taught by a registered physiotherapist.~The two intervention groups are manipulated every other day for 25-30 minutes each. A total number of interventions equal to or greater than 24 is considered a completed intervention.
Study: NCT05990218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intellegence. CADe syste,
Description: The patient received endoscopy under CADe system for polyp detection during second endoscopic withdrawal.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intellegence. CADe syste,
Description: The patient received endoscopy under CADe system for polyp detection during second endoscopic withdrawal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: The patient received endoscopy under conventional white light for polyp detection during second endoscopic withdrawal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: The patient received endoscopy under conventional white light for polyp detection during second endoscopic withdrawal.
Study: NCT05076175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Specified dose on specified days
Study: NCT06063317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CF33-CD19 IT
Description: Safety Run-In Phase: CF33-CD19 will be administered intratumorally on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.~Dose Escalation Combination Phase: CF33-CD19 will be administered intratumorally on Days 1 and 15 of each 28-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CF33-CD19 IT
Description: Safety Run-In Phase: CF33-CD19 will be administered intratumorally on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.~Dose Escalation Combination Phase: CF33-CD19 will be administered intratumorally on Days 1 and 15 of each 28-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CF33-CD19 IV
Description: Safety Run-In Phase: CF33-CD19 will be administered intravenously on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.~Dose Escalation Combination Phase: CF33-CD19 will be administered intravenously on Days 1 and 15 of each 28-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CF33-CD19 IV
Description: Safety Run-In Phase: CF33-CD19 will be administered intravenously on Days 1 and 8 of Cycle 1 and Day 1 of each subsequent 21-day cycle.~Dose Escalation Combination Phase: CF33-CD19 will be administered intravenously on Days 1 and 15 of each 28-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab will be infused via a 7-day continuous infusion from Days 2-9 and Days 16-23 of each 28-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab will be infused via a 7-day continuous infusion from Days 2-9 and Days 16-23 of each 28-day cycle.
Study: NCT06294769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: essencial oil of lavandula angustifolia
Description: The intervention will consist of the application of aromatherapy with 2% lavender essential oil cutaneously and inhalation via by a nurse, associated with usual care, in the immediate postoperative period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: grape seed vegetable oil
Description: The placebo group will only receive the application of grape seed vegetable oil associated with usual care in the immediate postoperative period.
Study: NCT06162494

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Zoster Vaccine
Description: After giving consent, participants will be given first dose of vaccine. Participants will be brought back 60-90 days post-vaccine for follow up testing and second dose of vaccine